biostudies-literatureNguyen TNMDeutsches Krebsforschungszentrum (DKFZ)Medical Research Council75https://www.ebi.ac.uk/biostudies/studies/S-EPMC9145441biostudies-literatureUnknown14(1)<h4>Background</h4>No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer's disease (AD) and vascular dementia (VD) so far.<h4>Methods</h4>Cox regression models with inverse probability of treatment weighting to model the underlying cardiovascular risk were used to assess the associations of low-dose ASA use with all-cause dementia, AD, and VD incidence in community-dwelling older adults from the German ESTHER study (N = 5258) and the UK Biobank (N = 305,394). Inclusion criteria were age of 55 years or older and completed drug assessment. Meta-analyses of the individual participant data from the two prospective cohort studies were performed.<h4Alzheimer's research & therapyLong-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies.PMC9145441MC_PC_17228MC_QA137853Stocker HNguyen TNMSchottker BBrenner HBeyreuther KChen LJTrares KHolleczek BfalseLong-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies.<h4>Background</h4>No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer's disease (AD) and vascular dementia (VD) so far.<h4>Methods</h4>Cox regression models with inverse probability of treatment weighting to model the underlying cardiovascular risk were used to assess the associations of low-dose ASA use with all-cause dementia, AD, and VD incidence in community-dwelling older adults from the German ESTHER study (N = 5258) and the UK Biobank (N = 305,394). Inclusion criteria were age of 55 years or older and completed drug assessment. Meta-analyses of the individual participant data from the two prospective cohort studies were performed.<h42022-01-01T00:00:00Z2022 May2026-05-09T16:35:32.328Z2024-11-13T08:35:15.018ZS-EPMC91454413562448710.1186/s13195-022-01017-4